We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+28.34%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$15.2B
AUM Growth
+$1.87B
Cap. Flow
+$90.5M
Cap. Flow %
0.6%
Top 10 Hldgs %
84.66%
Holding
125
New
12
Increased
14
Reduced
21
Closed
27

Top Buys

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$50.5M
2
AMRN
Amarin Corp
AMRN
+$43.1M
3
INSM icon
Insmed
INSM
+$26M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$19M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$10.8M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$22.4M
2
PHXM
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
+$20.8M
3
HALO icon
Halozyme
HALO
+$14.6M
4
EXEL icon
Exelixis
EXEL
+$11M
5
XNCR icon
Xencor
XNCR
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 91.42%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$3.94B 25.93%
51,046,060
– –
INCY icon
2
Incyte
INCY
$25.3B
$2.37B 15.59%
34,251,309
+275
+0% +$18.9K
ONC
3
BeOne Medicines Ltd
ONC
$34.1B
$2.06B 13.57%
11,959,824
– –
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$1.19B 7.83%
8,555,894
– –
GHDX
5
DELISTED
Genomic Health, Inc.
GHDX
$968M 6.38%
13,790,970
+396
+0% +$23.2K
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$12B
$735M 4.84%
7,583,084
– –
ACAD icon
7
Acadia Pharmaceuticals
ACAD
$4.46B
$590M 3.89%
28,439,114
+1,210,776
+4% +$19M
AMRN
8
Amarin Corp
AMRN
$294M
$554M 3.65%
1,703,475
+570,000
+50% +$43.1M
MDGL icon
9
Madrigal Pharmaceuticals
MDGL
$12.5B
$250M 1.65%
1,169,278
– –
ASND icon
10
Ascendis Pharma A/S
ASND
$16.7B
$201M 1.32%
2,837,352
– –
HRTX icon
11
Heron Therapeutics
HRTX
$92.5M
$159M 1.05%
5,025,298
– –
NVTA
12
DELISTED
Invitae Corporation
NVTA
$141M 0.93%
8,399,411
– –
DBVT
13
DBV Technologies
DBVT
$796M
$124M 0.82%
550,956
– –
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$118M 0.78%
2,513,462
– –
NBIX icon
15
Neurocrine Biosciences
NBIX
$18.3B
$116M 0.77%
944,624
– –
BCRX icon
16
BioCryst Pharmaceuticals
BCRX
$2.44B
$115M 0.76%
15,103,081
+1,090,909
+8% +$7.33M
ARRY
17
DELISTED
Array Biopharma Inc
ARRY
$86M 0.57%
5,656,196
– –
SAGE
18
DELISTED
Sage Therapeutics
SAGE
$80.2M 0.53%
567,497
-45,803
-7% -$7.07M
RYTM icon
19
Rhythm Pharmaceuticals
RYTM
$7.38B
$79M 0.52%
2,708,200
– –
CERS icon
20
Cerus
CERS
$577M
$77.5M 0.51%
10,749,937
– –
ARGX icon
21
argenx
ARGX
$55.2B
$77.3M 0.51%
1,019,557
+57,803
+6% +$5.12M
KNSA icon
22
Kiniksa Pharmaceuticals
KNSA
$6.13B
$76.5M 0.5%
3,000,000
– –
ONCE
23
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$75.5M 0.5%
1,384,130
– –
GWPH
24
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$68.5M 0.45%
396,700
+74,900
+23% +$10.8M
CBAY
25
DELISTED
Cymabay Therapeutics
CBAY
$54.5M 0.36%
4,917,700
– –
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2018 Portfolio in Review

As of Q3 2018, Baker Bros. Advisors held 125 positions worth $15.2B, up 14% from $13.3B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Baker Bros. Advisors's Q3 2018 filing shows 12 new, 14 increased, 21 reduced and 27 closed positions. Its largest new stake was Principia Biopharma Inc. Common Stock: 1,787,807 shares worth $52.2M. The largest sale was bluebird bio, an estimated $22.4M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q3 2018 buy was Principia Biopharma Inc. Common Stock: 1,787,807 shares worth $52.2M.
  • Baker Bros. Advisors added most to Amarin Corp in Q3 2018, an estimated $43.1M increase.
  • Baker Bros. Advisors's biggest Q3 2018 reduction was bluebird bio, cutting an estimated $22.4M.
  • Baker Bros. Advisors fully exited Exelixis in Q3 2018, selling an estimated $11M.
  • Baker Bros. Advisors's ten largest holdings make up 85% of its $15.2B portfolio in Q3 2018.
  • Baker Bros. Advisors opened 12 new positions and closed 27 in Q3 2018.
  • Baker Bros. Advisors's portfolio value rose 14% quarter-over-quarter to $15.2B.

Based on Baker Bros. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.